Law360, New York ( March 24, 2015, 10:41 AM EDT) -- On March 6, 2015, the U.S. Food and Drug Administration licensed the first ever U.S. biosimilar drug, Sandoz's Zarxio, a version of Amgen's Neupogen (filgrastim). On March 19, the Northern District of California denied Amgen's motion for a preliminary injunction against Sandoz's launch of Zarxio, removing the final barrier to U.S. consumers being able to obtain the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.